Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SPK-9001: Additional Ph I/II data

Data from the first 9 hemophilia B patients in an open-label, dose-escalation, U.S. and Australian Phase I/II trial showed that a single dose of 5x1011 vg/kg

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE